Goldline Pharmaceutical IPO will open for subscription on May 12, 2026, and close on May 14, 2026. The company aims to raise around ₹12 Crores through a Book Build Issue. The IPO consists entirely of a fresh issue of shares with a face value of ₹10 per equity share.
The Goldline Pharmaceutical IPO price band is fixed at ₹41 to ₹43 per share. The IPO will be listed on the BSE SME platform on May 19, 2026, while the allotment is expected to be finalized on May 15, 2026.
The company has shown steady financial growth over the last few years. Goldline Pharmaceutical reported revenue of ₹28.06 Crores in FY2025 compared to ₹23.57 Crores in FY2024. Profit also increased to ₹2.83 Crores in FY2025 from ₹1.81 Crores in FY2024. Based on the financial performance, long-term investors may keep this SME IPO on their watchlist.(Ipo Updates)
Goldline Pharmaceutical IPO Details
| Particulars | Details |
|---|---|
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹41 to ₹43 Per Share |
| Issue Size | Approx ₹12 Crores |
| Fresh Issue | Approx ₹12 Crores |
| Issue Type | Book Build Issue |
| IPO Listing | BSE SME |
| Allotment Date | May 15, 2026 |
| Listing Date | May 19, 2026 |
Goldline Pharmaceutical IPO GMP Today
The Grey Market Premium (GMP) of Goldline Pharmaceutical IPO is expected to be updated daily before listing. Investors usually track GMP to estimate possible listing gains and market sentiment.
Note: GMP is unofficial and can change anytime based on market demand.
Goldline Pharmaceutical IPO Review
Goldline Pharmaceutical Limited operates in the pharmaceutical marketing and distribution sector under the well-known Goldline brand. The company offers a wide range of pharmaceutical products across multiple healthcare specialties.
The company’s strong product portfolio, expanding state presence, and improving financials make this IPO attractive for SME investors looking for long-term growth opportunities.
Positive Factors
- Consistent revenue and profit growth
- Strong presence in pharmaceutical marketing
- Wide range of healthcare specialty products
- Expanding operations across multiple Indian states
- Healthy ROE and EBITDA margins
Risk Factors
- SME IPOs carry higher risk
- Competition in the pharma sector is intense
- Debt-to-equity ratio is relatively high
IPO Verdict
Considering the company’s financial growth and healthcare sector potential, investors with a long-term perspective may consider applying for this IPO.
Goldline Pharmaceutical IPO Market Lot
The minimum market lot for Goldline Pharmaceutical IPO is 6,000 shares.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 Lots | 6,000 Shares | ₹2,58,000 |
| Retail Maximum | 2 Lots | 6,000 Shares | ₹2,58,000 |
| S-HNI Minimum | 3 Lots | 9,000 Shares | ₹3,87,000 |
| S-HNI Maximum | 7 Lots | 21,000 Shares | ₹9,03,000 |
| B-HNI Minimum | 8 Lots | 24,000 Shares | ₹10,32,000 |
Goldline Pharmaceutical IPO Reservation
| Investor Category | Reservation |
|---|---|
| QIB | 50% |
| NII/HNI | 15% |
| Retail Investors | 35% |
Goldline Pharmaceutical IPO Important Dates
| Event | Date |
|---|---|
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Basis of Allotment | May 15, 2026 |
| Refund Initiation | May 18, 2026 |
| Credit to Demat Account | May 18, 2026 |
| IPO Listing Date | May 19, 2026 |
About Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical products under the Goldline brand name. The company operates through five business divisions:
- Goldline Pharma – Physicians, Orthopedics, ENT, Surgery, Neurology, Urology, and Gastroenterology.
- Goldline Cardinal – Cardiologists, Diabetologists, Endocrinologists, and General Physicians.
- Goldline Ayushman – Pediatric and child healthcare products.
- Goldline InLife – Critical care and specialty healthcare solutions.
- Goldline Wellness – Cancer therapy and wellness products.
The company sells products across multiple Indian states, including:
- Maharashtra
- Madhya Pradesh
- Odisha
- Jharkhand
- Tamil Nadu
- Rajasthan
- Bihar
All pharmaceutical products are marketed under the trusted Goldline brand.
Goldline Pharmaceutical IPO Financial Results
(Amount in ₹ Crores)
| Year | Revenue | Expenses | PAT | Assets |
|---|---|---|---|---|
| FY2023 | ₹19.85 | ₹19.45 | ₹0.26 | ₹19.39 |
| FY2024 | ₹23.57 | ₹21.04 | ₹1.81 | ₹22.93 |
| FY2025 | ₹28.06 | ₹24.20 | ₹2.83 | ₹26.28 |
The company has shown stable revenue growth along with improving profitability over the last three years.
Goldline Pharmaceutical IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE | 35.84% |
| ROCE | 38.46% |
| EBITDA Margin | 20.79% |
| PAT Margin | 10.10% |
| Debt to Equity Ratio | 1.50 |
| EPS (Basic) | ₹4.11 |
| RoNW | 27.38% |
| NAV | ₹12.39 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW | NAV |
|---|---|---|---|---|
| Mono Pharmacare Ltd. | 1.75 | 12.57 | 9.90% | 17.66 |
| Chandra Bhagat Pharma Ltd. | 1.14 | 37.73 | 2.86% | 39.72 |
Objects of the Issue
The company plans to utilize IPO proceeds for:
- Repayment or prepayment of borrowings
- Strengthening the balance sheet
- General corporate purposes
The company intends to use approximately ₹8.90 Crores for debt repayment.
Promoters of Goldline Pharmaceutical
The promoters of the company are:
- Amol Laxmikant Mujumdar
- Swapan Premprakash Khandelwal
Goldline Pharmaceutical IPO Lead Manager
Cumulative Capital Pvt. Ltd.
Goldline Pharmaceutical IPO Registrar
Bigshare Services Pvt. Ltd.
- Phone: +91-22-6263 8200
- Email: ipo@bigshareonline.com
Goldline Pharmaceutical IPO FAQs
What is the Goldline Pharmaceutical IPO?
Goldline Pharmaceutical IPO is an SME IPO through which the company plans to raise approximately ₹12 Crores.
What is the Goldline Pharmaceutical IPO Price Band?
The IPO price band is fixed at ₹41 to ₹43 per share.
What is the Goldline Pharmaceutical IPO Lot Size?
The minimum bid is 6,000 shares costing ₹2,58,000.
When will Goldline Pharmaceutical’s IPO open?
The IPO opens on May 12, 2026, and closes on May 14, 2026.
What is the Goldline Pharmaceutical IPO Allotment Date?
The allotment date is May 15, 2026.
What is the Goldline Pharmaceutical IPO Listing Date?
The IPO will list on BSE SME on May 19, 2026.
Should You Apply for Goldline Pharmaceutical IPO?
Investors looking for long-term opportunities in the pharmaceutical sector may consider this IPO after evaluating valuation and risk factors.
Disclaimer
The information shared here is intended solely for educational and general awareness purposes. Any securities, investments, or IPO-related details mentioned should not be interpreted as financial advice or investment recommendations. Readers are encouraged to conduct their own independent research or seek guidance from a qualified financial professional before making investment decisions.
IPO-related updates are provided for informational use only. Market trends, past performance, or investor interest do not ensure future outcomes. We are not registered with SEBI. Investments in IPOs and the securities market involve inherent risks, and individuals should carefully evaluate their financial situation or consult a certified financial advisor before investing.
